SEARCH

SEARCH BY CITATION

References

  • 1
    Everson GT. Natural history of hepatitis C. In: KoffRS, WuGY, eds. Chronic Viral Hepatitis: Diagnosis and Management. Totowa: Humana Press; 2001.
  • 2
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556562.
  • 3
    Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, Kam I. Evaluation of 100 patients for living donor liver transplantation. Liver Transpl 2000; 6:290295.
  • 4
    Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002; 346:10741082.
  • 5
    Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, et al. Living donor liver transplantation in hepatitis C patients: Short-term results compared with cadaveric transplantation. Am J Transpl 2001; 1S:316A.
  • 6
    Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8:S1418.
  • 7
    Davis GL, Balart LA., Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C, with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321:15011506.
  • 8
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:15061510.
  • 9
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347356.
  • 10
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492.
  • 11
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499.
  • 12
    Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347:975982.
  • 13
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman ML, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358:958965.
  • 14
    Hadziyannis S, Cheinquer H, Morgan T, Diago M, Jenson D, Sette HJ. Peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double-blind, multicenter study examining the effect of duration of treatment and RBV dose (abstract). J Hepatol 2002; 36:3.
  • 15
    Everson GT. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol [low-accelerating-dose-regimen]. Hepatology 2002; 36:297A.
  • 16
    Crippin, JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350355.